Studies with individual-level outcome data | Ìý | 41 | Ìý |
Population served* | Ìý | Ìý | Ìý |
 People who use drugs | 30 | Ìý | Ìý |
 Family, friends, others | 6 | Ìý | Ìý |
 Law enforcement personnel | 7 | Ìý | Ìý |
Location | Ìý | Ìý | Ìý |
 United States | 29 | Ìý | Ìý |
 C²¹²Ô²¹»å²¹ | 5 | Ìý | Ìý |
 United Kingdom | 5 | Ìý | Ìý |
 Other Europe†| 2 | Ìý | Ìý |
Follow-up method | Ìý | Ìý | Ìý |
 P²¹²õ²õ¾±±¹±ð | 18 | Ìý | Ìý |
 Prospectively scheduled | 12 | Ìý | Ìý |
 Only participants with follow-up included | 4 | Ìý | Ìý |
 Not specified (law enforcement personnel studies) | 7 | Ìý | Ìý |
Type of naloxone used | Ìý | Ìý | Ìý |
 I²ÔÂá±ð³¦³Ù±ð»å | 25 | Ìý | Ìý |
 N²¹²õ²¹±ô | 14 | Ìý | Ìý |
 B´Ç³Ù³ó | 2 | Ìý | Ìý |
Studies with community-level outcome data | Ìý | 5 | Ìý |
Location | Ìý | Ìý | Ìý |
 United States | 4 | Ìý | Ìý |
 United Kingdom | 1 | Ìý | Ìý |
Total studies‡ | Ìý | 44 | Ìý |